Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO). This treatment appeared to precipitate dialysis dementia, which was fatal in three patients. In two patients, continuous treatment with lower doses of DFO was possible. The development of dialysis dementia in chronic renal failure patients with very high serum aluminum levels may be a complication of DFO treatment.
Sherrard
D J
DJ
Department of Medicine, Seattle Veterans Administration Medical Center, WA 98108.
Walker
J V
JV
Boykin
J L
JL
D000328:Adult; D000535:Aluminum / Q000009:adverse effects*; D001847:Bone Diseases / Q000139:chemically induced / Q000150:complications / Q000628:therapy*; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D003704:Dementia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*
D000535:Aluminum; D003676:Deferoxamine